- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06620419
Klinisk undersøgelse af ekstern elektrisk stimulering til mandlig inkontinens
Klinisk evaluering af perineal elektrisk stimulering til urininkontinens hos mænd
The purpose of this research is to evaluate the effectiveness of the Elidah neuromuscular stimulation treatment to reduce incontinence in men post-prostatectomy.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Connecticut
-
Monroe, Connecticut, Forenede Stater, 06468
- Elidah
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Scheduled for robotic-assisted laparoscopic prostatectomy
- Read and speak English
- Predominant SUI of at least 1 pad/day
Exclusion Criteria:
- History or symptoms of urinary incontinence, urinary retention, extra-urethral incontinence, overflow incontinence
- Complete denervation of the pelvic floor
- Severe Obesity as defined by BMI >= 40
- Has undergone pre-op pelvic floor exercise strengthening
- Pelvic pain/painful bladder syndrome
- Implanted cardiac device, untreated cardiac arrhythmia or suffer from other heart problems.
- History of epilepsy
- Underlying neurologic/neuromuscular disorder
- Metal implants in the abdomen or pelvic area
- Chronic coughing
- Impaired decision making, suicidal thoughts, or drug/alcohol dependence
- Uncontrolled intercurrent illness that would limit compliance with study requirements
- Lacks capacity to adhere with study requirements
- Lacks capacity to consent for themselves.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Arm A: Scheduled for robotic assisted laparoscopic prostatectomy,
Scheduled for robotic assisted laparoscopic prostatectomy. |
Small controller that outputs stimulation for stress incontinence and OAB, attached to a male-anatomy thin GelPad placed in the perineal area.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
24-Hour Urine Leakage Measured by Pad Weight
Tidsramme: 6 weeks
|
Urine leakage was assessed using a 24-hour pad weight test. Participants wore absorbent pads for 24 hours, after which the pads were collected and weighed to quantify urine leakage in grams. The reported values represent the mean absolute 24-hour pad weight at Week 6, not the change from baseline. Lower values indicate less urine leakage. |
6 weeks
|
|
24-Hour Urine Leakage Measured by Pad Weight
Tidsramme: 12 weeks
|
Urine leakage was assessed using a 24-hour pad weight test. Participants wore absorbent pads for 24 hours, after which the pads were collected and weighed to quantify urine leakage in grams. The reported values represent the mean absolute 24-hour pad weight at Week 12, not the change from baseline. Lower values indicate less urine leakage. |
12 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants Without Adverse Events
Tidsramme: 6 weeks
|
The number of participants who did not experience an adverse event during the 6-week assessment period. Adverse events were assessed as part of the study's safety evaluation. |
6 weeks
|
|
Change in Incontinence Quality of Life (I-QOL) Score
Tidsramme: Baseline to 6 weeks
|
Urinary incontinence-related quality of life was assessed using the Incontinence Quality of Life (I-QOL) questionnaire. Each item is scored from 1 to 5. Item scores are summed and transformed to a total score ranging from 0 to 100, with higher scores indicating better quality of life. The reported outcome represents the change in total I-QOL score from baseline to Week 6, calculated as the Week 6 score minus the baseline score. Positive values indicate improved quality of life, while negative values indicate worsening quality of life. The possible change ranges from -100 to +100 points. |
Baseline to 6 weeks
|
|
Percentage Change in Daily Urinary Leakage Episodes
Tidsramme: Baseline to 6 weeks
|
Percentage reduction in the average number of urinary leakage episodes per day, including both stress and urge urinary incontinence episodes, from baseline to Week 6. Percentage reduction was calculated as [(baseline episodes per day - Week 6 episodes per day) / baseline episodes per day] × 100. Positive values indicate fewer leakage episodes, while negative values indicate an increase in leakage episodes. |
Baseline to 6 weeks
|
|
Percentage Change in Daily Urinary Leakage Episodes
Tidsramme: Baseline to 12 weeks
|
Percentage reduction in the average number of urinary leakage episodes per day, including both stress and urge urinary incontinence episodes, from baseline to Week 6. Percentage reduction was calculated as [(baseline episodes per day - Week 6 episodes per day) / baseline episodes per day] × 100. Positive values indicate fewer leakage episodes, while negative values indicate an increase in leakage episodes. |
Baseline to 12 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Gloria Kolb, MS,MBA, Elidah, Inc.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Sygdomme i det endokrine system
- Neoplasmer efter sted
- Neoplasmer
- Mandlige urogenitale sygdomme
- Urologiske sygdomme
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Genetiske sygdomme, medfødte
- Vandladningsforstyrrelser
- Nedre urinvejssymptomer
- Urologiske manifestationer
- Neoplasmer i endokrine kirtler
- Neoplastiske syndromer, arvelig
- Neoplasmer, multiple primære
- Multipel endokrin neoplasi
- Medfødte, arvelige og neonatale sygdomme og abnormiteter
- Patologiske tilstande, tegn og symptomer
- Tegn og symptomer
- Ufrivillig vandladning
- Multipel endokrin neoplasi type 1
Andre undersøgelses-id-numre
- TR-1168
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .